volume 16, issue 8, P769-775 1997
DOI: 10.1076/ceyr.16.8.769.8988
View full text
|
|
Share

Abstract: 5-Methylurapidil, an antagonist at the alpha 1A-adrenergic receptor subtype and an agonist at the 5-HT1A receptor subtype, lowers IOP predominantly by increasing outflow facility and may have potential for the therapy of glaucoma.